A population pharmacokinetic/toxicity model for the reduction of platelets during a 48-h continuous intravenous infusion of the histone deacetylase inhibitor belinostat

PURPOSE: Belinostat is a second-generation histone deacetylase inhibitor (HDI) predominantly metabolized by UGT1A1-mediated glucuronidation. Two common polymorphisms (UGT1A1*28 and UGT1A1*60) were previously associated with impaired drug clearance and thrombocytopenia risk, likely form increased dru...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Chemother Pharmacol
Egile Nagusiak: Peer, Cody J., Hall, Oliver M., Sissung, Tristan M., Piekarz, Richard, Balasubramaniam, Sanjeeve, Bates, Susan E., Figg, William D.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2018
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6410699/
https://ncbi.nlm.nih.gov/pubmed/29951694
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-018-3631-7
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak